NCT01278758View on ClinicalTrials.gov

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

November 30, 2010

Conditions
Metastatic Cancer
Interventions
DRUG

ASA404, DMXAA or DXAA

Trial Locations (4)

20850

Hematology /Oncology Associates, Rockville

46202

Indiana University Melvin and Bren Simon Cancer Center, Hematology/Oncology Dept., Indianapolis

48202

Joseph Ford Cancer Center/Clinical Trials Office, Henry Ford Health System, Detroit

98109-1023

Seattle Cancer Care Alliance, Seattle

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY